研究目的
To correlate CT parameters on detector-based dual-energy CT enterography (DECTE) with Crohn’s disease activity index (CDAI) and externally validate quantitative CT parameters.
研究成果
Iodine concentration measured on spectral detector-based DECTE represents an accurate, convenient, and reproducible biomarker for monitoring disease activity in CD.
研究不足
1. The number of patients in the study population was relatively small. 2. The study results might not be generalized to other DECT machines. 3. Histological confirmation was not performed in all patients. 4. CDAI was used as the reference standard. 5. Manual method for ROI analysis of the diseased bowel segments.
1:Experimental Design and Method Selection:
Retrospective study enrolling patients with CD who underwent spectral detector-based DECTE. Two radiologists reviewed DECTE images for qualitative and quantitative CT features.
2:Sample Selection and Data Sources:
39 patients with CD were enrolled, with an additional 33 patients for validation. Clinical and CT imaging characteristics were evaluated.
3:List of Experimental Equipment and Materials:
Spectral detector-based DECT scanner (IQon Spectral CT, Philips Healthcare), low Hounsfield unit enteric contrast agent (Easymark, Taejoon Pharmaceutical Co. Ltd.), intravenous contrast agent (iohexol; Bonorex 350, Central Medical Service).
4:Experimental Procedures and Operational Workflow:
Patients ingested contrast agent prior to CT scanning. Triphasic CT consisting of precontrast, enteric phase, and portal venous phase was performed. Iodine concentration maps were generated for analysis.
5:Data Analysis Methods:
Univariate statistical tests, Pearson’s correlation test, and multiple linear regression analyses were used to assess correlations between quantitative CT parameters and CDAI.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容